ClinicalTrials.gg
RecruitingNCT07849413Updated Sep 30, 2026

Visual Hallucinations in Lewy Body Diseases

An observational study in Lewy Body Disease, Lewy Body Dementia and Parkinson Disease, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by NYU Langone Health · Observational

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
234
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies in Lewy Body Disease with a site in United States — 32 open to participants now, 39 under way, 1 of them phase 3. Lewy Body Disease · United States.

Planned enrollment
15th of 31
234 · median 225
Started
2026
with 4 others
Observational
31 of 110
14 open now
Primary completion
2031-08
later than 35 of 38 live
Registered
110th of 110
by date
Lead sponsor
4 of 110
NYU Langone Health

Among the 110 studies in Lewy Body Disease with a site in United States, this one is the 15th largest by planned enrollment of the 31 observational ones that give a count, is one of 5 that started in 2026, is one of 31 observational ones, reaches primary completion later than 35 of the 38 other live ones, and was the 110th registered.

Lewy Body Disease

239 studies on the registry are indexed under Lewy Body Disease; 88 are open to participants now.

Browse Lewy Body Disease studies →

Open to participants now

32 of the 110 studies in Lewy Body Disease with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 63 Lewy Body Disease studies recruiting now, 41 (65%) set no upper age limit and none (0%) stop at 75 or younger; 10 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Lewy Body Disease with a site in United States, or all of them as a file.
02

Study summary

The goal of this basic experimental study involving humans (BESH) protocol is to improve the understanding of neural mechanisms underlying visual hallucinations in Lewy Body diseases to inform future treatment developments.

Read the detailed description

Visual hallucinations are highly prevalent in Lewy Body Diseases (LBD), a prominent group of neurodegenerative disorders that includes Dementia with Lewy Bodies, Parkinson's disease, and Parkinson's disease dementia. Currently, scientists do not fully understand how the brain creates these false visual images. This lack of knowledge makes it difficult to develop effective treatments.

This study aims to understand the neural mechanisms that give rise to these hallucinatory experiences. The study will include three groups of volunteers:

  1. LBD patients who experience visual hallucinations
  2. LBD patients who do not have visual hallucinations
  3. age-matched volunteers without a significant neurological history

During the study, participants will undergo safe, non-invasive brain imaging scans. While being scanned, they will either rest or complete visual computer tasks.

The results of this study will help map the brain networks responsible for visual hallucinations. These insights will help researchers develop better, targeted interventions for this disabling symptom.

03

Conditions studied

  • Lewy Body Disease
  • Lewy Body Dementia
  • Parkinson Disease
  • Parkinson Disease Dementia
  • Visual Hallucinations
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Three subject cohorts will be recruited for this study: 1) LBD patients who experience visual hallucinations (LBD-VH group); 2) patients diagnosed with LBD without any visual hallucinations (LBD-non-VH group, control arm); 3) age and demographically matched controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

I) LBD Patients with or without visual hallucinations

  1. 18 - 90 yrs
  2. Fluent in English or Spanish
  3. Score at least 24 out of 30 on the
  4. Diagnosed with Lewy Body diseases, including Parkinson's disease and Lewy Body dementias (Parkinson's disease dementia and dementia with Lewy bodies)

II) Age-matched controls (healthy volunteers)

  1. 18 - 90 yrs
  2. Fluent in English or Spanish
  3. Score at least 26 out of 30 on the MoCA

Exclusion criteria

Exclusion Criteria:

I) LBD Patients with or without visual hallucinations

  1. History of traumatic brain injury or significant head trauma
  2. History of significant neurologic disorders other than Lewy body diseases
  3. Meets criteria for substance abuse or dependence
  4. For MRI studies, any to MRI as determined by the MRI Safety Screening Form

II) Age-matched controls (healthy volunteers)

  1. History of traumatic brain injury or significant head trauma
  2. History of significant neurologic disorders other than Lewy body diseases
  3. Meets DSM-IV criteria for substance abuse or dependence
  4. For MRI studies, any contraindication to MRI as determined by the MRI Safety Screening Form
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
234 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Lewy Body Diseases who experience visual hallucinations

    Patients will complete between one and multiple outpatient experimental sessions, depending on the specific scientific question being addressed, the type of data required by the investigator and the patient's availability. Potential interventions include: behavioral tasks, MRI scans, MEG scans.

    Behavioral: Behavioral Tasks · Other: MRI/MEG Scans

  • Patients with Lewy Body Diseases who do not experience visual hallucinations

    Patients will complete between one and multiple outpatient experimental sessions, depending on the specific scientific question being addressed, the type of data required by the investigator and the patient's availability. Potential interventions include: behavioral tasks, MRI scans, MEG scans.

    Behavioral: Behavioral Tasks · Other: MRI/MEG Scans

  • Age-matched controls

    Patients will complete between one and multiple outpatient experimental sessions, depending on the specific scientific question being addressed, the type of data required by the investigator and the patient's availability. Potential interventions include: behavioral tasks, MRI scans, MEG scans.

    Behavioral: Behavioral Tasks · Other: MRI/MEG Scans

Interventions

  • BehavioralBehavioral Tasks

    Delivered as part of outpatient experimental sessions.

  • OtherMRI/MEG Scans

    Delivered as part of outpatient experimental sessions.

06

What researchers measure

Primary outcomes

  1. Changes in recognition rate

    Behavioral responses assessed by changes in recognition rate from pre- to post-disambiguation stage.

    Time frame: Pre-Disambiguation Stage, Post-Disambiguation Stage (Study Visit: 1 Day)

  2. Euclidean distance in neural activity patterns

    Neural response patterns assessed by Euclidean distance in neural activity pattern between pre- and post-disambiguation stages.

    Time frame: Pre-Disambiguation Stage, Post-Disambiguation Stage (Study Visit: 1 Day)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request by the time of publication or, the end of the period of performance, including any no-cost extension. Data will remain available for at least as long as required by the applicable repository and/or journal policies. De-identified behavioral and fMRI data underlying peer-reviewed publications will be shared through established repositories, such as OpenNeuro, GitHub, and figshare. Data will be shared by the time of publication or, for other findings, by the end of the award's period of performance, and will remain available for at least as long as required by the applicable repository and/or journal policies. Repository links will be provided when available. All potentially identifying information will be fully removed prior to releasing the data.

Time frame: Data will become available by the time of publication or, the end of the period of performance, including any no-cost extension. Data will remain available for at least as long as required by the applicable repository and/or journal policies.

Access criteria: The investigator who proposes to use the data will be granted access upon reasonable request. De-identified behavioral and fMRI data underlying peer-reviewed publications will be shared through established repositories, such as OpenNeuro, GitHub, and figshare. Data will be shared by the time of publication or, for other findings, by the end of the award's period of performance, and will remain available for at least as long as required by the applicable repository and/or journal policies. Repository links will be provided when available

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2031, 59 months after the start.

Of 45 observational studies under Lewy Body Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 171. This study's planned 59 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Sep 30, 2026
StartActual
Sep 15, 2026
Primary completionEst.
Aug 31, 2031
CompletionEst.
Aug 31, 2031
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849413
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Sep 15, 2026
Primary completion
Aug 31, 2031 (estimated)
Completion
Aug 31, 2031 (estimated)
Last update
Sep 30, 2026

Study contacts

Yuan-hao Wu
Contact
Yuanhao.Wu@nyulangone.org
212.263.0307
Nalini Jeet
Contact
Nalini.Jeet@nyulangone.org
212-263-0228
Biyu He, PhD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion